Model‐based dose optimization framework for bedaquiline, pretomanid and linezolid for the treatment of drug‐resistant tuberculosis

K Mehta, T Guo, PH Van der Graaf… - British Journal of …, 2024 - Wiley Online Library
Aims Bedaquiline, pretomanid and linezolid (BPaL) combination treatment against
Mycobacterium tuberculosis is promising, yet safety and adherence concerns exist that …
被引用次数：2 相关文章

Model-based Dose Optimization Framework for Bedaquiline, Pretomanid, and Linezolid for the Treatment of Drug-Resistant Tuberculosis.

K Mehta, T Guo, PH Van der Graaf… - British Journal of …, 2023 - europepmc.org
Aim Bedaquiline, pretomanid, and linezolid combination (BPaL) treatment against
Mycobacterium tuberculosis is promising yet safety and adherence concerns exist that …

Model-based dose optimization framework for bedaquiline, pretomanid and linezolid for the treatment of drug-resistant tuberculosis

K Mehta, T Guo, PH van der Graaf… - British journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
Aims Bedaquiline, pretomanid and linezolid (BPaL) combination treatment against
Mycobacterium tuberculosis is promising, yet safety and adherence concerns exist that …
[PDF] universiteitleiden.nl

[PDF][PDF] Model-based dose optimization framework for bedaquiline, pretomanid and linezolid for the treatment of drug-resistant tuberculosis

K Mehta, T Guo, PH van der Graaf… - 2023 - scholarlypublications …
Aims: Bedaquiline, pretomanid and linezolid (BPaL) combination treatment against
Mycobacterium tuberculosis is promising, yet safety and adherence concerns exist that …
[PDF] universiteitleiden.nl

[PDF][PDF] Model-based dose optimization framework for bedaquiline, pretomanid, and linezolid for the treatment of drug-resistant tuberculosis

K Mehta, T Guo… - Quantitative …, 2023 - scholarlypublications …
Aim: Bedaquiline, pretomanid, and linezolid combination (BPaL) treatment against
Mycobacterium tuberculosis is promising yet safety and adherence concerns exist that …